BioMarin updated 2024 guidance sees EPS raise, but no change to revenue [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
For the year, the company is still projecting revenues of $2.7B-$2.8B. Consensus is $2.76B. Non-GAAP diluted EPS guidance was raised to $2.75-$2.95 from $2.60-$2.80. Consensus is $2.75. In Q1, BioMarin ( BMRN ) missed on the top line but beat on the bottom Vimizim continued to be the company's best-selling drug, with sales up 2% year over year to $192.6M. Voxzogo, its second-best selling drug, saw sales grow 74% to $152.9M. Non-GAAP income of $139.7M was a 21% increase from the prior-year period. Non-GAAP diluted EPS of $0.71 compares to $0.60 in the year-ago period. More on BioMarin Pharmaceutical Recommended For You More Trending News Recommended For You More Trending News About BMRN Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- 4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 4/24/24 - Beat
BMRN
Sec Filings
- 5/2/24 - Form 144
- 5/2/24 - Form 144
- 4/26/24 - Form 10-Q
- BMRN's page on the SEC website